Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ461461,51,10
KB5225231,36
PKN54,0254,11,35
Msft214,34214,50,00
Nokia4,26254,267-1,56
IBM126,171270,00
Daimler AG40,9240,9351,92
PFE38,338,60,00
05.08.2020 10:11:47
Indexy online
AD Index online
select
AD Index online
 

  • 05.08.2020 9:58:44
Innate Pharma (IPH.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
5,43 2,26 0,12 267 709
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.08.2020
Popis společnosti

Business Summary: Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Innate Pharma SA revenues decreased 14% to EUR69M. Net loss applicable to common stockholders totaled EUR20.8M vs. income of EUR3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Depreciation & Amortization in R&D increase from EUR6.7M to EUR15.5M (expense).



  • Poslední aktualizace: 05.08.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardPetr Neubauer4307.09.201007.09.2010
Chairman of the Management BoardPetr Bina4707.09.201007.09.2010
Member of the Management BoardJiri Hriba-01.01.2013
Member of the Management BoardAles Jelinek4207.09.201007.09.2010